PRELIMINARY AMENDMENT

U.S. Application No.: 10/522,737

Attorney Docket No.: Q86049

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

Claim 1. (currently amended):

A method for treating beta-thalassaemia, comprising

administering to a subject in need of treatment an effective amount Use of angelicin or a structural

analogue thereof for the preparation of a medicament for the therapeutic treatment of beta-

thalassaemia.

Claim 2. (currently amended):

The method Use according to claim 1, wherein the

structural analogue is selected from the group consisting of linear and angular coumarins, optionally

substituted, heteroanalogues of angelicin, thiopyrano-benzofurans, acylangelicins, alkylangelicins,

alkoxycarbamoylangelicins, psoralens, and isopsoralens, optionally substituted.

Claim 3. (currently amended):

The method Use according to claim 2, wherein the

structural analogue is bergapten.

Claim 4. (currently amended):

The method Use according to claim 1, wherein the

angelicin or structural analogue is in combination with at least one further modifier of the

transcription process.

PRELIMINARY AMENDMENT Attorney Docket No.: Q86049

U.S. Application No.: 10/522,737

Claim 5. (currently amended): The method Use according to Claim 4 in which the further modifier of the transcription process is selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).